INTERVIEW WITH FERNANDO MALUF
Latin American Oncology Group (LACOG), a Cooperative Group Consensus

INTERVIEW WITH CHARLES RYAN
APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study

INTERVIEW WITH SILKE GILLESSEN & AURELIUS OMLIN
The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - SPOP mutations in prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Christopher Barbieri presented his work evaluating the role of SPOP mutations in prostate cancer. SPOP point mutations were identified in prostate cancer by his group after whole exome sequencing in 2012, but the functional significance of these mutations had yet to be explored.

auaSome prostate cancers were also recently shown to be hallmarked by chromoplexy, a mechanism where multiple genomic alterations occur simultaneously while multiple chromosomal sites are broken, ligated, and rearranged, often associated with loss of some genetic material. Interestingly, SPOP mutations were mutually exclusive from the well-known ETS family rearrangements, leading Dr. Barbieri to evaluate the association of chromoplexy, SPOP mutations, and DNA repair pathways.

Using an elegant cell-line model, he was able to show that under normal conditions, DNA damage is repaired via homologous recombination (HR), which is a high-fidelity repair pathway. However, when the level of SPOP is reduced, cells are forced to repair DNA damage using nonhomologous end joining (NHEJ), which is error-prone. This model would potentially explain the phenomenon of chromoplexy and has therapeutic ramifications because cells which are dependent on NHEJ repair tend to be sensitive to both platinum adducts and PARP inhibitors.

He closed by noting that platinum-based chemotherapy has been used in prostate cancer before but did not show benefit. He reasoned that a signal may have been lost because only 10-15% of patients harbor SPOP mutations. Appropriate patient selection which matches tumor biology with rationale-based therapy may therefore result in better oncologic outcomes.

AUA/NCI Specialized Programs of Research Excellence (SPORE) Joint Workshop

Presented by Christopher E. Barbieri, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

New York, NY USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe